Welcome to our dedicated page for Yarrow Bioscience SEC filings (Ticker: VYNE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Yarrow Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Yarrow Bioscience's regulatory disclosures and financial reporting.
Yarrow Bioscience, Inc. has a significant shareholder group reported by ADAR1 Capital Management, LLC and Daniel Schneeberger. Private investment funds managed by ADAR1 Capital Management beneficially own 59,000 shares of Yarrow’s common stock, representing 8.8% of the class based on 668,327 shares outstanding as of June 30, 2026.
Both ADAR1 Capital Management and Daniel Schneeberger report shared voting and dispositive power over these 59,000 shares, with no sole voting or dispositive power. Schneeberger files as a control person of ADAR1 Capital Management, a Texas investment adviser, and the filing is made on a joint basis under a joint filing agreement.
venBio Global Strategic Fund V, L.P. and its general partner, venBio Global Strategic GP V, LLC, report their beneficial ownership in Yarrow Bioscience, Inc. common stock. As of July 27, 2026, they may have been deemed to beneficially own 294,139 shares, consisting of 152,881 shares held directly and 141,258 shares issuable within 60 days upon exercise of pre-funded warrants, subject to a blocker. As of the more recent reporting date, they may be deemed to beneficially own 279,340 shares, composed of the same 152,881 shares plus 126,459 shares issuable upon warrant exercise, also subject to the blocker.
These positions represent approximately 9.99% of Yarrow’s outstanding common stock at both reference dates, based on issuer-reported outstanding share counts adjusted for the exercisable warrants. The reporting persons share voting and dispositive power over 279,340 shares and have no sole voting or dispositive power.
Yarrow Bioscience, Inc., formerly VYNE Therapeutics Inc., filed a post-effective amendment to its Form S-3 to reflect completion of its merger with Yarrow Bioscience Operating Company Corp. and its name change to Yarrow Bioscience, Inc. The filing establishes a shelf registration allowing the company to offer and sell, from time to time, up to $250.0 million of common stock, preferred stock and warrants. Within this, an Amended and Restated Sales Agreement with TD Securities (USA) LLC permits an “at the market” program for up to $50.0 million of common stock, which is included in the $250.0 million capacity. As of August 10, 2026, 2,669,746 shares of common stock were outstanding. Proceeds from any offerings may be used for research and development of its lead antibody candidate YB‑101 for autoimmune thyroid diseases, along with working capital and other general corporate purposes. The company is a clinical-stage biotechnology issuer and qualifies as a smaller reporting company, which allows scaled disclosure requirements.
Yarrow Bioscience, Inc. (formerly VYNE Therapeutics Inc.) filed an amended report to provide full historical and pro forma financial information for the July 27, 2026 merger with privately held Yarrow Bioscience, Inc. (now Yarrow Bioscience Operating Company Corp.). The company is a clinical-stage biotech developing YB-101, a monoclonal antibody targeting the thyroid stimulating hormone receptor for Graves’ disease and thyroid eye disease.
Pre-Merger Yarrow raised $100.0 million in Series A funding in December 2025 and paid a $70.0 million upfront fee to GenSci for an exclusive ex-China license to YB-101, with up to $1.295 billion in potential milestones and tiered royalties in the low to low‑mid teens. It recorded a net loss of $71.0 million from inception to December 31, 2025 and a further $9.3 million loss for the six months ended June 30, 2026.
Cash was $100.0 million at December 31, 2025 and $18.7 million at June 30, 2026, before considering $100.0 million of pre‑closing financing. Management states this liquidity is expected to fund operations for at least 12 months. The merger is accounted for as a reverse recapitalization with Yarrow as the accounting acquirer, based on an exchange ratio of 0.7171 VYNE shares per Yarrow share.
Yarrow Bioscience, Inc. (formerly VYNE Therapeutics) reports that for the six months ended June 30, 2026 it generated $0.2 million in royalty revenue and incurred a net loss of $6.6 million, a substantial reduction from $14.4 million a year earlier, primarily due to sharply lower research and development spending as legacy programs were wound down ahead of its merger with Yarrow.
Cash and cash equivalents were $22.9 million and total assets $23.6 million, with liabilities of only $1.5 million, leaving stockholders’ equity at $22.1 million as of June 30, 2026 and no debt outstanding. The company completed a strategic merger with privately held Yarrow, changed its name, effected a 1‑for‑50 reverse stock split, declared a pre‑closing $17.3 million special cash dividend, and increased authorized common shares to support its new clinical‑stage focus on YB‑101 for Graves’ disease and thyroid eye disease. Management states that, giving effect to the merger, existing cash is expected to fund operations for at least 12 months from the financial statement issuance date, and Finacea royalty revenues are expected to cease after December 31, 2026 following LEO Pharma’s license termination.
Zhang Xiaofan filed Amendment No. 3 reporting beneficial ownership of common stock of Yarrow Bioscience, Inc.. The filing states beneficial ownership of 162,452 shares of common stock, representing 0.6% of the class. These shares are reported with both sole and shared voting and dispositive power.
Yarrow Bioscience, Inc. has a significant institutional holder group led by Logos Global Management LP and related funds and managers, which jointly report beneficial ownership of 286,308 shares of common stock, representing 10.7% of the class based on 2,669,788 shares outstanding as of July 29, 2026. Within this group, Logos Global Master Fund LP holds 176,678 shares (6.6%) and Logos Opportunities Fund V LP holds 109,630 shares (4.1%), with all voting and dispositive powers held on a shared, not sole, basis. The group also references prefunded warrants to acquire an additional 2,201,030 shares, which are excluded from the reported ownership due to a 9.99% beneficial ownership limitation. The filers state the securities are held for investment in the ordinary course and not for the purpose of changing or influencing control of Yarrow Bioscience.
Janus Henderson Group Ltd., through its investment adviser subsidiaries, reports beneficial ownership of Yarrow Bioscience, Inc. common stock on a passive basis. The group is deemed to beneficially own 266,712 shares of common stock, representing 9.99% of the class, all held across various managed client accounts.
In addition, the Asset Managers may be deemed to beneficially own 1,895,248 pre-funded warrants that are subject to a 9.99% ownership limitation, preventing exercise if it would push ownership above that threshold. Janus Henderson has no sole voting or dispositive power, but shared voting and dispositive power over the 266,712 shares. Economic benefits, including dividends and sale proceeds, belong to the underlying managed portfolios, notably including Janus Henderson Biotech Innovation Master Fund Ltd. for positions exceeding five percent.
OrbiMed-affiliated funds report a new Schedule 13D stake in Yarrow Bioscience, Inc. common stock following the merger of a wholly owned subsidiary of VYNE Therapeutics Inc. with Yarrow. OrbiMed Advisors LLC and related entities beneficially own 266,306 Shares, representing 9.97% of the 2,669,788 Shares outstanding as disclosed in a recent company report.
In the merger, OrbiMed Private Investments X, LP received 233,019 Shares and pre-funded warrants to purchase 4,084,827 Shares, while OrbiMed Genesis Master Fund, L.P. received 33,287 Shares and warrants to purchase 583,545 Shares. The warrants carry a 9.99% Beneficial Ownership Limitation and an exercise price of $0.0001 per Share, so they are currently not exercisable due to this blocker.
OrbiMed states the position was acquired for investment purposes and that it may increase or decrease its holdings over time. OrbiMed Advisors and its general-partner entities share voting and dispositive power over the funds’ Shares. OrbiMed Advisors member Mona Ashiya, who serves on Yarrow’s board, is party to a 180-trading-day lock-up agreement restricting sales and certain other transactions in her Shares following the merger.
Yarrow Bioscience, Inc. has a significant shareholder group led by Logos Global Management LP and related entities, which report beneficial ownership of up to 9.9% of the company’s common stock. This stake is held through combinations of common shares and prefunded warrants, all subject to a 9.99% beneficial ownership limitation.
The ownership percentages are calculated using 2,669,788 shares of common stock outstanding as of July 29, 2026. The reporting persons state that the securities are not held for the purpose of changing or influencing control and that they disclaim beneficial ownership beyond their pecuniary interests.